» Articles » PMID: 15541325

Life Expectancy and Prognostic Factors for Survival in Patients with Polycythemia Vera and Essential Thrombocythemia

Overview
Journal Am J Med
Specialty General Medicine
Date 2004 Nov 16
PMID 15541325
Citations 127
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

Methods: The study sample consisted of 831 consecutive patients with polycythemia vera (n = 396; 4184 person-years of follow-up) or essential thrombocythemia (n = 435; 4304 person-years of follow-up). Mortality in each group was compared with the Italian population using the standardized mortality ratio (SMR) based on life expectancy data obtained from the Italian Institute of Statistics.

Results: The 15-year survival was 65% in patients with polycythemia and 73% in those with thrombocythemia. By Cox regression analysis, the independent predictors of death were a history of thrombosis for polycythemia (hazard ratio [HR] = 2.2; P = 0.0002) and thrombocythemia (HR = 2; P = 0.01), and male sex (HR = 1.8; P = 0.03) for thrombocythemia. Mortality compared with the general population was 1.6-fold higher (P <0.001) in patients with polycythemia but was not increased in those with thrombocythemia (SMR = 1; P = 0.8).

Conclusion: Life expectancy of patients with polycythemia vera (especially if younger than 50 years) was reduced compared with the general population, whereas life expectancy of patients with essential thrombocythemia was not affected significantly by the disease, reflecting the more indolent nature of the proliferation. History of thrombosis was the main predictor of death in both diseases.

Citing Articles

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Beauverd Y, Ianotto J, Thaw K, Sobas M, Sadjadian P, Curto-Garcia N Leukemia. 2025; .

PMID: 40074852 DOI: 10.1038/s41375-025-02545-2.


JAK2 V617F Mutation Leading to Portal Vein Thrombosis in a Young Patient: A Case Report.

Patil C, Ananthu V, Junaid M, Lavanya P, Jabeen S Cureus. 2025; 16(12):e76547.

PMID: 39877786 PMC: 11772894. DOI: 10.7759/cureus.76547.


Essential thrombocytosis transformed AML with TP53 mutations and its clinical implications.

Si Y, Wang J, Hambly B, Wang Y, Zhang Y, Bao S Discov Oncol. 2024; 15(1):786.

PMID: 39692923 PMC: 11655794. DOI: 10.1007/s12672-024-01665-y.


Prognostic and Predictive Models in Myelofibrosis.

Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K Curr Hematol Malig Rep. 2024; 19(5):223-235.

PMID: 39179882 PMC: 11416430. DOI: 10.1007/s11899-024-00739-6.


Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events.

Saelue P, Sinthujaroen P, Suwiwat S, Thongsuksai P Clin Appl Thromb Hemost. 2024; 30:10760296241263099.

PMID: 39053144 PMC: 11282546. DOI: 10.1177/10760296241263099.